Update on ENESTop: TFR in CML after discontinuing nilotinib

The ENESTop trial (NCT01698905) investigated treatment-free remission (TFR) in patients with chronic myeloid leukemia (CML) after discontinuing nilotinib, following the acheivement of a deep molecular... Author: VJHemOnc Added: 09/21/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts

Related Links:

This study demonstrated the critical role of the ABL gene in maintaining CML cell survival and tumorigenicity in vitro and in vivo. ABL gene editing-based therapy might provide a potential strategy for imatinib-insensitive or resistant CML patients.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Revised Funding Information.
Source: Supportive Care in Cancer - Category: Cancer & Oncology Source Type: research
Conclusion: Monocytopenia, especially anemia, was the most common type of cytopenia. The cytopenia was predominantly grade 2, developed in majority of the patients within 6 months after imatinib initiation, and had resolved by 24-36 months after imatinib initiation. PMID: 32454829 [PubMed]
Source: Advances in Hematology - Category: Hematology Tags: Adv Hematol Source Type: research
The advent of tyrosine kinase inhibitors (TKIs) targeted therapy revolutionized the treatment of chronic myeloid leukemia (CML) patients. However, cardiotoxicity associated with these targeted therapies puts the cancer survivors at higher risk. Ponatinib is a third-generation TKI for the treatment of CML patients having gatekeeper mutation T315I, which is resistant to the first and second generation of TKIs, namely, imatinib, nilotinib, dasatinib, and bosutinib. Multiple unbiased screening from our lab and others have identified ponatinib as most cardiotoxic FDA approved TKI among the entire FDA approved TKI family (total 50+).
Source: International Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Contributors : Daisuke Kodama ; Masakazu Tanaka ; Toshio Matsuzaki ; Kimiko Izumo ; Nobuaki Nakano ; Eiji Matsuura ; Mineki Saito ; Masahiro Nagai ; Masahisa Horinouchi ; Atae Utsunomiya ; Hiroshi Takashima ; Ryuji Kubota ; Shuji IzumoSeries Type : Expression profiling by arrayOrganism : Homo sapiensHuman T-cell leukemia virus type 1 (HTLV-1) causes incurable adult T-cell leukemia and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Patients with HAM/TSP have increased levels of HTLV-1-infected cells compared with asymptomatic HTLV-1 carriers. However, the roles played by cellular genes in HTLV-1-infect...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Homo sapiens Source Type: research
AbstractInherited polymorphic sequence variations in drug transport genes likeABCB1 impact a portion of patients with hematologic malignancies that show intrinsic or acquire resistance to treatment. Keeping in view inter-individual sensitivities for such drugs, we through this case –control study tested whetherABCB1 C3435T and G2677T polymorphisms have any influence on the risk and treatment response in patients with chronic myeloid leukemia (CML) and B-acute lymphoblastic leukemia (B-ALL). Genotyping forABCB1 polymorphisms was performed by polymerase chain reaction-restriction fragment length polymorphism in 100 CML...
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research
SummaryThe recent American Society of Hematology (ASH) annual meeting, held in Orlando, Florida, in December 2019 was an exciting meeting for researchers and clinicians working in the field of chronic myeloid leukemia (CML), as well as for patients suffering from the disease. Interesting updates were presented on new kinase inhibitors (TKI) demonstrating great potential with low toxicities in heavily pretreated patients. Moreover, the 10-year follow-up data of the ENESTnd Study, comparing 2nd generation (2ndG) TKI nilotinib with imatinib showed a  continuous benefit of the 2ndG TKI in achieving deeper molecular respon...
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research
Publication date: June 2020Source: Clinical Lymphoma Myeloma and Leukemia, Volume 20, Issue 6Author(s): Olga V. Lazareva, Anna G. Turkina, Ekatarina Yu. Chelysheva, Anton A. Kulikovsky, Maria V. Galayko, Olga M. Senderova, Valentina M. Pepeliaeva, Sergey V. Meresiy, Alexandr S. Luchinin, Galina I. Milutina, Lyubov V. Gavrilova, Lyudmila B. Avdeeva, Elena B. Dasheeva, Olga Yu. Vinogradova, Hunan L. Julhakyan, Sergey M. Kulikov
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Conclusion: Moderate anemia is a common concomitant symptom in CML-CP patients and is associated with high-risk CML, but its occurrence does not affect the survival of CML-CP patients in TKI era. PMID: 32432512 [PubMed - in process]
Source: Hematology - Category: Hematology Tags: Hematology Source Type: research
Tyrosine kinase inhibitors represent the standard of care for several diseases and drug targets in hematologic malignancies. Infectious complications vary by disease status and prior therapy, but overall incidence of infections generally is low. In chronic diseases, such as chronic myeloid leukemia and chronic lymphocytic leukemia, patients can remain on tyrosine kinase inhibitor therapy for many years, with few infectious complications from therapy. Bruton tyrosine kinase inhibitors overall are well tolerated in lymphoproliferative disorders, with long-term follow-up of many years in patients with chronic lymphocytic leuk...
Source: Infectious Diseases Clinics of North America - Category: Infectious Diseases Authors: Source Type: research
More News: Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Leukemia | Nilotinib | Tasigna